Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$112.51 USD
-3.13 (-2.71%)
Updated Oct 4, 2024 03:05 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLDPF 112.51 -3.13(-2.71%)
Will ZLDPF be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why
Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Other News for ZLDPF
Catalyst Watch: Tesla's Robotaxi reveal, AI events for Nvidia, AMD, and HP Enterprise
Zealand Pharma initiated with neutral view at Deutsche Bank, here's why
Terns stock jumps as weight loss drug succeeds in early trial
Zealand Pharma management to meet with Cantor Fitzgerald
Novo Nordisk warns of continued Ozempic shortage in Q4